All conditions

Muscular Dystrophy

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

711
Trials on record
119
Recruiting now
10
Australian sites
9
Phase 3 trials
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Muscular Dystrophy →

Get alerts when Muscular Dystrophy trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Muscular Dystrophy

Muscular dystrophy is the name given to a group of genetic conditions that cause the muscles in the body to gradually weaken and break down over time. It happens because certain genes that are responsible for building and maintaining healthy muscle tissue are not working as they should. There are actually many different types of muscular dystrophy, and they can vary quite a lot in terms of which muscles are affected, how quickly symptoms progress, and when they first appear. Some types show up in early childhood, while others may not become noticeable until adulthood.

In Australia, muscular dystrophy is more common than many people might expect. Muscular Dystrophy Australia estimates that around 1 in every 1,000 Australians lives with some form of muscular dystrophy or a related neuromuscular condition. It affects people of all backgrounds, and while some types are more common in males, others affect both males and females equally. Because it is a genetic condition, it can sometimes run in families, though in some cases it appears with no previous family history at all.

When it comes to managing the condition, care is usually provided by a team of different health professionals working together. This might include neurologists, physiotherapists, respiratory specialists, cardiologists, and others depending on the type of muscular dystrophy and the muscles involved. While there is currently no cure for most forms, there are many ways to help manage symptoms, maintain strength and mobility for as long as possible, and support quality of life. Your medical team will be the best source of guidance about what options are most relevant to your specific situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Muscular Dystrophy in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

Research pipeline

Where trials for Muscular Dystrophy currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Muscular Dystrophy.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Muscular Dystrophy by country. Australia is highlighted.

Showing the top 10 of 49 countries with trial sites.

Clinical trials for Muscular Dystrophy

Showing 134 of 134 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT00592553 · PTC Therapeutics Phase 2 · 11 countries Completed
Completed Phase 2 Est. completion 31 December 2009
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇪🇸 ES +3 more

**Who might be able to join this trial:** - You are able to read and sign a consent form (or a parent/guardian can sign on your behalf if you are under 18) - You are male - You are 5 years of age or older - You have shown signs of Duchenne or Becker muscular dystrophy (such as muscle weakness, an unusual walking style...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00799266 · Novartis Pharmaceuticals Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 5 March 2018
🇦🇺 AU🇨🇦 CA🇭🇺 HU🇷🇺 RU🇿🇦 ZA🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with a chronic rheumatological condition (such as arthritis), inflammatory bowel disease, or Duchenne muscular dystrophy, and have needed steroid medication (by mouth or by drip) at some point in the past 12 months - Your bone density scan of the lower...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT01197300 · Novartis Pharmaceuticals Phase 3 · 6 countries Completed
Completed Phase 3 Est. completion 27 February 2019
🇦🇺 AU🇨🇦 CA🇭🇺 HU🇷🇺 RU🇿🇦 ZA🇬🇧 GB

**Who might be able to join this trial:** **Group 1 (patients from the previous related study):** - Children and teenagers, boys or girls, aged 6 to 19 years old, who took part in the earlier related study (called the "Core study"), took at least one dose of the study medication, and completed a specific visit in that...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02285062 · Celgene Phase 3 · 21 countries Completed
Completed Phase 3 Est. completion 15 March 2019
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇮🇪 IE🇮🇱 IL +13 more

Who might be able to join this trial: - You have been confirmed by a tissue biopsy to have a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (Activated B-Cell type) - You have been recently diagnosed with this lymphoma and have not yet received any treatment for it - Your lymphoma can be seen and measure...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02760264 · ReveraGen BioPharma, Inc. Phase 2 · 6 countries Completed
Completed Phase 2 Est. completion 1 May 2018
🇦🇺 AU🇨🇦 CA🇮🇱 IL🇸🇪 SE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - A parent or legal guardian must have signed a consent form before any study-related steps begin - The child must have a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD), verified by a central genetic counselor, based on specific test results and a clinical picture co...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03039686 · Hoffmann-La Roche Phase 3 · 13 countries Completed
Completed Phase 3 Est. completion 28 April 2020
🇦🇷 AR🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP +5 more

**Who might be able to join this trial:** - You have been diagnosed with Duchenne Muscular Dystrophy (DMD), confirmed by medical records and a genetic test - You are able to walk without any help or assistive devices - You scored at least 15 points on a specific walking ability test called the North Star Ambulatory Ass...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03179631 · PTC Therapeutics Phase 3 · 18 countries Completed
Completed Phase 3 Est. completion 5 March 2022
🇦🇺 AU🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇳 CN Hong Kong🇮🇳 IN🇯🇵 JP +10 more

**Who might be able to join this trial:** - You must be male - You must be 5 years old or older - You must have been diagnosed with Duchenne Muscular Dystrophy based on physical signs and symptoms - Your Duchenne Muscular Dystrophy must be caused by a specific type of gene change called a "nonsense point mutation" in t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03439670 · ReveraGen BioPharma, Inc. Phase 2 · 11 countries Completed
Completed Phase 2 Est. completion 23 February 2021
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇬🇷 GR🇮🇱 IL🇳🇱 NL🇪🇸 ES +3 more

**Who might be able to join this trial:** - A parent or legal guardian must agree to the study in writing, and the child will also be asked for their agreement - The child must have a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD), verified by a central genetics team - The child must be at least 4 years old...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03703882 · Catabasis Pharmaceuticals Phase 3 · 8 countries Completed
Completed Phase 3 Est. completion 22 September 2020
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇮🇪 IE🇮🇱 IL🇸🇪 SE🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You (or your child's) legal guardian must be willing and able to sign a consent form agreeing to take part in the trial - You have been diagnosed with Duchenne muscular dystrophy (DMD), confirmed by high levels of a specific muscle enzyme in the blood and a genetic test showi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04060199 · NS Pharma, Inc. Phase 3 · 19 countries Completed
Completed Phase 3 Est. completion 19 October 2023
🇦🇺 AU🇨🇦 CA🇨🇱 CL🇨🇳 CN🇬🇷 GR Hong Kong🇮🇹 IT🇲🇽 MX +11 more

**Who might be able to join this trial:** - You are a boy who is at least 4 years old but younger than 8 years old - You have been confirmed to have a specific type of Duchenne Muscular Dystrophy (DMD) where a particular gene repair strategy (targeting a section called "exon 53") could help - You are able to walk on yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06867107 · Satellos Bioscience, Inc. Phase 2 · 1 country By Invitation
By Invitation Phase 2 Est. completion 30 August 2026
🇦🇺 AU

**Who might be able to join this trial:** - You must have already taken part in the related "parent" clinical trial called SAT-3247-CL-101. - Your steroid medication dose (if you take one) must have stayed the same since the parent trial, or you must not be taking steroids at all. - Any other regular medicines, supple...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05004129 · AMO Pharma Limited Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇦🇺 AU🇨🇦 CA🇳🇿 NZ🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Congenital or Childhood Onset Myotonic Dystrophy Type 1 (DM1), confirmed through genetic testing, and are between 6 and 45 years old — OR you are joining directly from completing a specific earlier related study called AMO-02-MD-2-003. - Your doc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05481879 · Dyne Therapeutics Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2029
🇦🇺 AU🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇳🇿 NZ🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a type of Myotonic Dystrophy Type 1 (DM1) where the genetic repeat causing the condition is larger than 100 repeats. - Your muscle symptoms from DM1 started when you were 12 years old or older. - You have noticeable muscle stiffness (myotonia), me...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05996003 · NS Pharma, Inc. Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 11 September 2026
🇦🇺 AU🇨🇦 CA🇯🇵 JP🇳🇿 NZ🇰🇷 KR Turkey (Türkiye)🇺🇸 US

**Who might be able to join this trial:** - You are a boy aged 4 years old or older, but younger than 15 years old - You have a confirmed genetic change in the dystrophin gene that could be helped by a technique called "exon 44 skipping" (confirm with trial site if unsure) - You are able to walk on your own without any...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06131983 · Arrowhead Pharmaceuticals Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇦🇺 AU🇨🇦 CA🇩🇪 DE🇮🇹 IT🇳🇱 NL🇳🇿 NZ🇪🇸 ES🇹🇭 TH

**Who might be able to join this trial:** - You have been diagnosed with FSHD1 (a type of muscular dystrophy) confirmed by genetic testing - Your disease severity falls in the middle range of a 0–10 scale (between 3 and 8) - A scan (MRI) shows that you have a suitable leg muscle that can be safely used for a biopsy (sm...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06138743 · Arrowhead Pharmaceuticals Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇦🇺 AU🇳🇿 NZ🇹🇼 TW🇹🇭 TH

Who might be able to join this trial: - You have been diagnosed with Myotonic Dystrophy Type 1 (DM1) confirmed by genetic testing - A doctor has observed signs of DM1, including noticeable muscle stiffness (myotonia) - Your DM1 symptoms first appeared after the age of 12 - You are able to walk at least 10 meters (about...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06185764 · Vertex Pharmaceuticals Incorporated Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 2 February 2027
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇪🇸 ES +2 more

Who might be able to join this trial: - You have been officially diagnosed with a condition called Myotonic Dystrophy Type 1 (DM1), and your symptoms first appeared after the age of 1 year - You have had a genetic test that confirmed your DM1 diagnosis, showing a specific genetic marker (called a CTG repeat) of at leas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06844214 · Sanofi Phase 2 · 6 countries Recruiting
Recruiting Phase 2 Est. completion 28 February 2029
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇮🇱 IL🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - For Part A: You are between 18 and 55 years old (inclusive) at the time of signing the consent form. - For Part B: You are between 10 and 17 years old, OR between 18 and 55 years old (inclusive) at the time of signing the consent form. - You have myotonic dystrophy type 1 (D...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06847282 · University of Kansas Medical Center Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇦🇺 AU🇺🇸 US

**Who might be able to join this trial:** - Be between 5 and 17 years old - Have been diagnosed with FSHD (type 1 or type 2) confirmed through genetic testing - Have noticeable muscle weakness in the face, shoulders, core, or limbs - Be able to walk 10 meters (about 33 feet) on your own in under 12 seconds without help...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT07160634 · Solid Biosciences Inc. Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 1 January 2029
🇦🇺 AU🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You are able to walk on your own. - You have a confirmed diagnosis of Duchenne muscular dystrophy (DMD) and a genetic test has identified a specific DMD gene change linked to the condition. - A blood test shows you do not have antibodies against a common virus called adeno-as...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07287189 · Satellos Bioscience, Inc. Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 31 March 2027
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇵🇱 PL🇷🇸 RS🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of Duchenne muscular dystrophy (DMD), backed by genetic testing that found a mutation in the DMD gene. - Boys with DMD who are able to walk and are aged 7 years or older but younger than 10 years at the time of screening. - Boys who have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT00847379 · PTC Therapeutics Phase 2 · 11 countries Terminated
Terminated Phase 2 Est. completion 24 May 2010
🇦🇺 AU🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇪🇸 ES +3 more

**Who might be able to join this trial:** - You must have already completed the treatment phase of the previous related study (called PTC124-GD-007-DMD). - You must be able to sign a consent form agreeing to take part (if you are under 18, a parent or guardian must also sign, and you may be asked to sign an assent form...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02090959 · PTC Therapeutics Phase 3 · 19 countries Terminated
Terminated Phase 3 Est. completion 12 June 2018
🇦🇺 AU🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇦 CA🇨🇱 CL🇨🇿 CZ🇫🇷 FR +11 more

**Who might be able to join this trial:** - You must have already completed the treatment period in the previous related Phase 3 clinical trial (called PTC124-GD-020-DMD). - You (and/or your parent or legal guardian, if you are a minor) must have signed and dated a consent form showing you have been fully informed abou...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT04632940 · Kyntra Bio Phase 3 · 11 countries Terminated
Terminated Phase 3 Est. completion 12 June 2023
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇨🇦 CA🇨🇳 CN🇫🇷 FR🇮🇹 IT🇳🇱 NL +3 more

**Who might be able to join this trial:** - You are a boy between 6 and just under 12 years old at the time of screening - You (and/or your parent or legal guardian) are willing and able to give written consent to participate - You have been diagnosed with Duchenne Muscular Dystrophy (DMD) and a genetic test has confi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05854433 · Wake Forest University Health Sciences Not Applicable · 1 country By Invitation
By Invitation Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** **If you have Myotonic Dystrophy Type 2 (DM2):** - You are between 30 and 65 years old - You have been diagnosed with DM1 or DM2 through genetic testing or by a doctor's assessment (if diagnosed by assessment only, a close blood relative must have had a positive genetic test)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00004568 · National Institute of Neurological Disorders and Stroke (NINDS) Not Applicable · 2 countries Recruiting
Recruiting Not Applicable
Mali🇺🇸 US

**Who might be able to join this trial:** - You have a known or suspected inherited (genetic) neurological condition, OR you are a blood relative (any degree of relation) of someone who has a genetic neurological condition, even if you are not affected yourself. - You are able to understand and sign a consent form, OR...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00082108 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Duchenne Muscular Dystrophy (DM), Facioscapulohumeral Muscular Dystrophy (FSHD), or a related disease - You are a family member who has not been diagnosed with one of these diseases but has a relative who has been diagnosed with DM, FSHD, or a related...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00138931 · University of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - People of any age with a suspected inherited heart or muscle/nerve condition may be considered. - Families where more than one member has been affected by such a condition are particularly being sought. Who may not be able to join: - People who do not have a suspected inherited...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00272883 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2050
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with, or are suspected to have, a congenital myopathy (a muscle condition present from birth) - Family members of people with a congenital myopathy diagnosis or suspected diagnosis Who may not be able to join: - People whose condition is myotonia c...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00313677 · Katherine Mathews Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2030
🇺🇸 US

Who might be able to join this trial: - You have elevated levels of a muscle enzyme in your blood called creatine kinase (a sign that muscle may be breaking down) - You have been diagnosed with a condition called a dystroglycanopathy, confirmed by a muscle tissue test, a genetic test showing a known gene change, or a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00390104 · Boston Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a type of muscular dystrophy, either based on your symptoms or test results. - You are a close family member (such as a parent, child, or sibling) of someone who has been diagnosed with muscular dystrophy. - If you have been diagnosed with a neuromusc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01403402 · Cure CMD Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇺🇸 US

Who might be able to join this trial: - People diagnosed with a muscle condition related to Alpha 7 or Alpha 9 Integrin proteins. - People diagnosed with a Collagen VI related muscle condition (ranging from Ullrich to Bethlem types). - People diagnosed with an Alpha-Dystroglycan related muscular dystrophy (including Dy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01484678 · University of Florida Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** - Boys and young men (ages 5–30) who have been diagnosed with Duchenne Muscular Dystrophy (DMD), whether or not they can still walk - A DMD diagnosis may be based on symptoms starting before age 5, very high levels of a muscle enzyme in the blood, a missing or very low protein...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01694940 · Columbia University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇦 CA🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with, or your doctor suspects you may have, a mitochondrial disorder. - You are an adult who is known to carry a mutation in your mitochondrial DNA (genetic material passed down through families). - Your lab test results suggest you may have a mitochondria...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02069756 · The Duchenne Registry Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Duchenne or Becker muscular dystrophy - Women who carry the gene for Duchenne or Becker muscular dystrophy and do show some symptoms are also included - Women who carry the gene for Duchenne or Becker muscular dystrophy but do not show any symptoms ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02398786 · Myotonic Dystrophy Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2030
🇺🇸 US

"Who might be able to join this trial: - People who have been diagnosed with myotonic dystrophy type 1 (DM1) or type 2 (DM2) — including the congenital form (present from birth), juvenile-onset (starting in childhood), or adult-onset form — confirmed by a clinical examination or a genetic test. Who may not be able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03058185 · Pitié-Salpêtrière Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 July 2033
🇫🇷 FR

**Who might be able to join this trial:** - You have a confirmed harmful mutation in the LMNA and/or EMD gene. - You are regularly seen by a doctor or medical team in France. - You are willing to sign a consent form agreeing to take part in the trial. **Who may not be able to join:** - You do not wish to sign the cons...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03373968 · Italfarmaco Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2029
🇧🇪 BE🇨🇦 CA🇫🇷 FR🇩🇪 DE🇮🇱 IL🇮🇹 IT🇳🇱 NL🇷🇸 RS +3 more

**Who might be able to join this trial:** - People who took part in a previous clinical study of Givinostat for Duchenne Muscular Dystrophy (DMD) and completed their final study visit, OR people who were screened for a specific earlier Givinostat study (DSC/14/2357/48), met all the entry requirements for that study, h...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03882827 · Genethon Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 30 May 2029
🇧🇪 BE🇫🇷 FR🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - You must be a boy - You must be between 4 and 9 years old (inclusive) - Your weight or BMI must be at or below the 95th percentile for your age (not significantly above the healthy range for your size) - You must have a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03981575 · Virginia Commonwealth University Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇦 CA🇩🇪 DE🇮🇹 IT🇳🇱 NL🇳🇿 NZ🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 70 years old (inclusive) - You are able to understand and agree to participate in the study on your own - You have been diagnosed with Myotonic Dystrophy Type 1 (DM1) either through a clinical diagnosis (based on muscle stiffness, muscle weakness in cer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04001582 · Newcastle University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2040
🇬🇧 GB

Who might be able to join this trial: - You have been diagnosed with Facioscapulohumeral Muscular Dystrophy (FSHD), or your diagnosis is currently being confirmed. - You live in the United Kingdom. Who may not be able to join: - You have been diagnosed with a different neuromuscular disease (a condition affecting the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04003363 · Newcastle University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇬🇧 GB

Who might be able to join this trial: - Anyone who has been diagnosed with Myotonic Dystrophy, confirmed through genetic testing, or who is currently waiting for a diagnosis to be confirmed. Who may not be able to join: - There are no stated reasons that would prevent someone from joining this registry. Important: Al...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04012671 · Ning Wang, MD., PhD. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2039
🇨🇳 CN

Who might be able to join this trial: - Children and adults who are older than 2 years of age - People who have been diagnosed with Duchenne Muscular Dystrophy (a genetic muscle-weakening condition), including female carriers of the condition, where the diagnosis has been confirmed through genetic testing - People whos...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04369209 · Ning Wang, MD., PhD. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2031
🇨🇳 CN

**Who might be able to join this trial:** - People of any age and any gender may be eligible to take part. - People who have been diagnosed with FSHD1 (a specific type of muscular dystrophy) confirmed by a specialised genetic test, whether or not they currently have symptoms. - Healthy individuals who are not related t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04626674 · Sarepta Therapeutics, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been formally diagnosed with Duchenne muscular dystrophy (DMD), confirmed through medical records and genetic testing. - Depending on which group (cohort) you are placed in, you may need to be a certain age — ranging from 2 years old up to under 18 years old — and e...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04906460 · Wave Life Sciences USA, Inc. Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 27 June 2026
🇯🇴 JO🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - Patients who have been diagnosed with Duchenne muscular dystrophy (DMD) based on their symptoms and clinical assessment - Patients who have a confirmed genetic change in the DMD gene that can be targeted by a specific type of treatment called "exon 53 intervention" - Patient...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05016908 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) confirmed through genetic testing, or healthy individuals with no known muscular dystrophy (genetic testing may not be required for healthy participants). - People who are able and wil...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05019625 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2) through genetic testing and/or clinical features, including those who have tested positive but have no symptoms, or those with characteristic features who have not had genetic testing done. - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05020002 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2), either through genetic testing or based on symptoms — even if you haven't had genetic testing done. - You are a healthy person with no known muscular dystrophy (for comparison purposes in the study). -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05102799 · Rigshospitalet, Denmark Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇩🇰 DK

Who might be able to join this trial: - People who have two disease-causing changes (variants) in a gene called anoctamin-5. - People who have had a specific type of MRI scan (called T1-weighted MRI) of the muscles in the lower back and legs. Who may not be able to join: - People who have other conditions that can als...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05102916 · University of Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2071
🇨🇭 CH

Who might be able to join this trial: - You have been diagnosed with a neuromuscular disease (a condition affecting the muscles and/or the nerves that control them) - You are a child, teenager, or adult - You live in Switzerland or receive treatment for your condition in Switzerland - You have agreed to take part and g...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05224778 · Virginia Commonwealth University Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇮🇹 IT🇺🇸 US

Who might be able to join this trial: - The child must be between newborn age and 3 years and 11 months old at the time of enrollment. - The child must have been diagnosed with Congenital Myotonic Dystrophy (CDM), meaning they showed symptoms of myotonic dystrophy as a newborn (within the first 30 days of life) — such...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05230459 · AskBio Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman between 18 and 65 years old with a diagnosis of a muscle disease called LGMD2I/R9, confirmed by a genetic test showing a change in the FKRP gene. - You are able to walk or run 10 meters in less than 30 seconds. - You are able to understand and follow al...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05237973 · National Institute of Neurological Disorders and Stroke (NINDS) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 August 2026
🇺🇸 US

**Who might be able to join this trial:** **For healthy volunteers:** - You are an adult aged 18 or older in generally good health (some controlled conditions like high blood pressure are acceptable) - You are willing and able to follow all study procedures and attend for the full duration of the study - You are able...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05394506 · Institut National de la Santé Et de la Recherche Médicale, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - You have a mutation in the LMNA gene that has led to a diagnosis of a condition called "laminopathy" that affects the muscles - You have symptoms of the disease, such as muscle weakness or tendon tightening, with or without breathing or heart problems - You are either the fir...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05412394 · Anne M. Connolly Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2026
🇺🇸 US

Who might be able to join this trial: - The participant must be between 1 month and 30 months old - The participant must show signs of muscle weakness consistent with Duchenne muscular dystrophy, have a specific blood marker (creatine kinase) that is at least 20 times higher than the normal level, and have a confirmed...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05532813 · Assistance Publique - Hôpitaux de Paris Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2026
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with Myotonic Dystrophy Type 1 (DM1), confirmed by a genetic test - You are between 18 and 70 years old - You are able to walk, even if you need a walking stick for support - Your level of muscle involvement falls within a specific range on a disease s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05554835 · LMU Klinikum Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2040
🇦🇹 AT🇩🇪 DE🇮🇹 IT

Who might be able to join this trial: - You have a suspected or confirmed diagnosis of mitochondrial disease - You are willing to take part in the trial Who may not be able to join: - You are not willing to take part in the trial Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05902351 · Hereditary Neuropathy Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇺🇸 US

**Who might be able to join this trial:** - People of any age (children, teenagers, or adults) who have been diagnosed with or are suspected to have Charcot-Marie-Tooth disease (CMT) or another inherited nerve condition - People who have been diagnosed based on family history, clinical tests (such as nerve tests or phy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05933057 · Italfarmaco Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 1 February 2028
🇧🇪 BE🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇵🇱 PL +4 more

**Who might be able to join this trial:** - Boys aged 9 to 17 years old at the time of screening - Those who are able to give written agreement to take part, either by the patient themselves and/or their parent or legal guardian, as required by local rules - Those who have been diagnosed with Duchenne muscular dystrop...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05982119 · Centre Hospitalier Universitaire de Liege Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇧🇪 BE🇨🇿 CZ🇪🇬 EG🇭🇺 HU🇵🇱 PL🇷🇴 RO🇸🇮 SI

**Who might be able to join this trial:** *For patients with a neuromuscular condition:* - People with a confirmed genetic diagnosis of Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy type 1 (DM1), Charcot-Marie-Tooth disease (CMT), or FKRP gene mutations, or a conf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05989620 · Virginia Commonwealth University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇺🇸 US

Who might be able to join this trial: - You are between 6 and 50 years old at the time of joining the trial - You have muscle weakness that a doctor has noticed during a physical examination, mainly affecting muscles closer to the center of the body (like hips, thighs, or shoulders) - You have been confirmed through ge...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06075693 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a condition called Myotonic Dystrophy Type 1 (DM1), either through genetic testing and/or based on symptoms — even if you have no symptoms yet, or if you chose not to have genetic testing done. - You are an "unaffected" participant, meaning you ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06079567 · Centre Hospitalier Universitaire de Nice Not Applicable · 5 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇧🇪 BE🇫🇷 FR🇮🇹 IT🇳🇱 NL🇪🇸 ES

**Who might be able to join this trial:** - You have been confirmed through genetic testing to have FSHD2, meaning you have a specific change in the SMCHD1 gene and a related genetic feature called a D4Z4 4qA allele - You are between 18 and 75 years old - You have noticeable muscle weakness in your arms or legs - Your...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06093100 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇺🇸 US

Who might be able to join this trial: - You are male and aged 10 years or older - You have been diagnosed with Duchenne Muscular Dystrophy (DMD), confirmed either through a muscle biopsy or a genetic test - If you are 18 or older, you are able to give your own consent to take part - If you are under 18, a parent or gua...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06124196 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2030
🇺🇸 US

**Who might be able to join this trial:** *For people with Duchenne Muscular Dystrophy (DMD):* - People who are male - People aged 10 years or older - People who have a confirmed diagnosis of DMD, shown through a muscle biopsy or genetic testing - People aged 18 or older who can provide their own signed consent to par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06132750 · Radboud University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇳🇱 NL

Who might be able to join this trial: - People who are willing and able to take part in measurements at the Radboudumc hospital in Nijmegen, or if visiting in person is not possible, participation through home visits may be arranged instead. - People who have a confirmed genetic diagnosis of LAMA2-related muscular dyst...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06138639 · Solid Biosciences Inc. Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 6 May 2027
🇨🇦 CA🇮🇹 IT🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - Children in different age groups may be eligible, ranging from newborns up to under 18 years old, depending on which part of the trial (cohort) they would join. - Depending on the cohort, participants may need to be able to walk and complete a 10-meter walk or run test in under 3...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06185673 · Benitec Biopharma, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2030
🇺🇸 US

**Who might be able to join this trial:** - People who were previously enrolled in a related natural history study called BNTC-OPMD-NH-001 and completed at least 6 months of follow-up in that study. - People who gave written consent before any study procedures began. - People aged 50 to 65 years at the time of enrolli...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06224660 · Sardocor Corp. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Duchenne Muscular Dystrophy (DMD), confirmed by a genetic test - You have a type of heart disease (cardiomyopathy) where scarring has been found in at least 3 out of 16 sections of the heart's main pumping chamber - Your heart is pumping less than...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06227182 · Radboud University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇳🇱 NL

Who might be able to join this trial: - You are between 18 and 70 years old. - You are willing and able to give your consent to take part in the study. - You are able to read and understand written and spoken instructions in Dutch. - You are willing and able to understand what the study involves and what it is about....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06300307 · ARTHEx Biotech S.L. Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 1 July 2027
🇨🇦 CA🇫🇷 FR🇮🇹 IT🇳🇱 NL🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been officially diagnosed with a condition called Myotonic Dystrophy Type 1 (DM1), confirmed by a genetic blood test showing more than 150 repeats of a specific gene change - You are able to walk on your own and can complete a 10-meter walk or run test without using...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06316778 · Université de Sherbrooke Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇨🇦 CA

**Who might be able to join this trial:** - You have been officially diagnosed with myotonic dystrophy type 1 (DM1) with an adult form of the condition - You experience leaking urine due to stress (such as when coughing or sneezing), sudden urges to urinate, or a combination of both - You are able to give your own free...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06354790 · Institut de Myologie, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - A parent or legal guardian must provide signed consent, and children aged 6 and older must also provide their own agreement to take part - People who have a clinical diagnosis of LAMA2-related muscular dystrophy (LAMA2-RD), confirmed either by two faulty copies of the LAMA2...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06366815 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2024
🇮🇹 IT

Who might be able to join this trial: - Boys who have been diagnosed with Duchenne Muscular Dystrophy confirmed by genetic testing - Boys with Duchenne Muscular Dystrophy who have lost the ability to walk independently - A parent or guardian must be able to provide consent for the child to take part Who may not be abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06402942 · Başak Çağla Arslan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 August 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - You have been diagnosed with Duchenne muscular dystrophy. - You are able to read and write in Turkish. - You have scored 27 points or more on a standard memory and thinking test called the Modified Mini Mental Test (confirm with trial site). - You have access to a computer or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06503367 · Nationwide Children's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇺🇸 US

Who might be able to join this trial: - The patient (or their parent or legal guardian) must have signed a consent form, and the patient must agree to participate if old enough to do so. - The patient must be aged from birth up to (but not including) 5 years old at the time of consent. - The patient must have a confirm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06517498 · Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with Facioscapulohumeral Muscular Dystrophy (a genetic muscle condition that typically affects the face, shoulders, and upper arms) Who may not be able to join: - No specific exclusion criteria have been listed for this trial (confirm with trial site) Im...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06523400 · Lupin Ltd. Phase 3 · 6 countries Recruiting
Recruiting Phase 3 Est. completion 17 March 2026
🇧🇪 BE🇩🇰 DK🇩🇪 DE🇮🇹 IT🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2) confirmed by genetic testing. - People who are able to understand and willing to sign a consent form (or, for those under 18, whose parent or legal guardian signs the form and who themselves...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06564974 · Catalyst Pharmaceuticals, Inc. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 February 2032
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - The patient (or their parent/legal guardian) is willing and able to sign a consent form after being told what the registry involves, before anything registry-related begins - The patient and/or their parent or guardian is willing and able to fill out quality-of-life questionn...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06574919 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇪🇬 EG

**Who might be able to join this trial:** - Children and teenagers between 2 and 18 years old - People who have been diagnosed with a muscular dystrophy that is **not** Duchenne Muscular Dystrophy (DMD), confirmed through physical examination, lab tests, and genetic testing - Children whose parents or guardians agree t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06600308 · Centre Hospitalier Universitaire Dijon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇫🇷 FR

**Who might be able to join this trial:** - You are an adult (18 years or older) - You have given written consent to take part in the trial - You have been officially diagnosed with facioscapulohumeral muscular dystrophy (FSH) through genetic testing - You are able to understand and follow the instructions for the diff...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06641895 · Shanghai Jiao Tong University School of Medicine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - The child's parent or legal guardian fully understands what the study involves and agrees to participate by signing a consent form - The child is a boy who can walk on his own and is at least 4 years old but not yet 8 years old - The child has been diagnosed with Duchenne Mu...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06667453 · PepGen Inc Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇦 CA🇳🇿 NZ🇬🇧 GB

**Who might be able to join this trial:** - You have a confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1), shown by a genetic test finding at least 100 CTG repeats in the DMPK gene - You experience myotonia (muscle stiffness or difficulty relaxing muscles after use) - You have enough muscle tissue in both lower leg...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06692426 · Masonic Cancer Center, University of Minnesota Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 3 March 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Duchenne muscular dystrophy (DMD), confirmed by a genetic test showing a mutation in the DMD gene and/or a muscle biopsy showing no dystrophin protein - You are not able to walk (non-ambulatory) - You have a specific small muscle in both feet (ca...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06716931 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with myotonic dystrophy type 2 (DM2), confirmed by genetic testing, and are between 18 and 70 years old. - You are able to walk on your own without any help from another person or a walking aid (such as a cane or walker). - You have had a normal heart...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06721299 · Jeffrey Statland Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 February 2028
🇺🇸 US

Who might be able to join this trial: - People who have a genetically confirmed diagnosis of facioscapulohumeral muscular dystrophy (FSHD) type 1 or type 2, or a clinical diagnosis of FSHD type 1 with a close biological relative (parent, sibling, or child) who has a confirmed genetic mutation for the condition - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06747884 · Virginia Commonwealth University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

**Who might be able to join this trial:** **Congenital Myotonic Dystrophy (CDM) Group:** - Children aged 5 to 17 years and 11 months at the time of joining (the lower age limit may not apply for children who completed a previous study called ASPIRE-DM1, and the upper age limit may not apply for those who took part in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06755138 · Seoul National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇰🇷 KR

**Who might be able to join this trial:** *If you have Duchenne Muscular Dystrophy (DMD):* - You have been diagnosed with Duchenne Muscular Dystrophy through genetic testing. - You are older than 10 years and younger than 30 years. - Your upper limb function falls within a specific mid-range on a scale called the Broo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06769633 · Italfarmaco Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2029
🇧🇪 BE🇮🇹 IT🇳🇱 NL🇬🇧 GB

**Who might be able to join this trial:** **Core Phase (first 48 weeks):** - Boys aged 2 years old up to (but not including) 6 years old at the time of screening - A parent or legal guardian must provide written consent, and the child must provide written agreement if required by local rules - People who have been con...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06773988 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇧🇪 BE

Who might be able to join this trial: - You are over 18 years old and have been diagnosed with Duchenne Muscular Dystrophy (DMD), which is a genetic condition that causes progressive muscle weakness - You currently use a non-invasive ventilator (a breathing support machine that helps you breathe through a mask, without...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06813443 · IRCCS Azienda Ospedaliero-Universitaria di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with cardiomyopathy (a condition affecting the heart muscle) according to current international medical guidelines - People who were at least 12 years old at the time of their cardiomyopathy diagnosis - For people under 18 years old, both the young...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06817382 · Insmed Gene Therapy LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2028
🇺🇸 US

**Who might be able to join this trial:** - The child must have been born male, and be between 3 and just under 5 years old (Part 1) or between 2 and just under 3 years old (Part 2) when the parent or guardian signs the consent form. - The child must be able to walk at least 10 meters on their own, without help from a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06900049 · Shanghai Jiao Tong University School of Medicine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 20 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - The participant must be a boy between 4 and 8 years old (including those who are exactly 4 or 8) at the start of screening - The participant must have been diagnosed with Duchenne Muscular Dystrophy (DMD), a muscle-weakening condition, confirmed by genetic testing that shows...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06911190 · Radboud University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇳🇱 NL

**Who might be able to join this trial:** - You previously took part in the FSHD-FOCUS 2 study and have a genetically confirmed diagnosis of FSHD (facioscapulohumeral muscular dystrophy), and you have been told about this genetic confirmation. - You previously took part in the FSHD-iFocus study as a child/young person...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06924125 · Hospital Universitari Vall d'Hebron Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2030
🇪🇸 ES

Who might be able to join this trial: - You have symptoms that match the condition AND genetic testing has found 2 faulty copies of the LAMA2 gene, OR a muscle biopsy has shown low levels of a protein called laminin alpha2 along with at least one faulty copy of the LAMA2 gene. - You (or your legal guardian) have signed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06925269 · Red Nucleus Enterprise Solutions, LLC Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** **For patients (Group A):** - You must have been taking the medication Givinostat for at least 2 years - You must be at least 10 years old, with a parent or legal guardian who has agreed to your participation - You must currently be taking Givinostat - You must be willing and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07015632 · Seoul National University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
🇰🇷 KR

Who might be able to join this trial: - You have been officially diagnosed with Duchenne Muscular Dystrophy (DMD) through genetic testing - You are older than 10 years and younger than 30 years old - Your upper limb function falls within a specific range on a scale called the Brooke Scale, scoring between 2 and 5 (conf...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07037862 · Entrada Therapeutics, Inc. Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 28 March 2029
🇧🇪 BE🇮🇹 IT🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - You have been diagnosed with Duchenne muscular dystrophy (DMD) through genetic testing, and your specific genetic change is the type that could be treated by a technique called "exon 44 skipping," as confirmed by a genetic counselor connected to the trial. - You were assigned...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07038200 · Avidity Biosciences, Inc. Phase 3 · 10 countries Recruiting
Recruiting Phase 3 Est. completion 1 May 2028
🇨🇦 CA🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇳🇱 NL🇪🇸 ES +2 more

Who might be able to join this trial: - People who have been diagnosed with FSHD1 or FSHD2 through both clinical assessment and genetic testing - People who are able to walk at least 10 metres on their own at a set pace during the screening visit (walking aids such as leg braces or ankle supports are permitted) - Peopl...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07038824 · Entrada Therapeutics, Inc. Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇧🇪 BE🇮🇹 IT🇳🇱 NL🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People who have a confirmed genetic diagnosis of Duchenne muscular dystrophy (DMD), specifically with a change in the dystrophin gene that could be addressed by a technique called "exon 45 skipping," as reviewed by a specialist genetic counsellor. - People who were assigned m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07039799 · Istanbul University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 February 2027
Turkey (Türkiye)

Who might be able to join this trial: - People who have been clinically diagnosed with Duchenne Muscular Dystrophy (DMD) - People aged 7 years or older - People who are able to walk as well as people who are not able to walk (both are eligible) - People who are able to understand and follow instructions involving movem...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07058662 · Belief BioMed (Beijing) Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇨🇳 CN

Who might be able to join this trial: - The participant (and/or their legal guardian) must be willing and able to give written consent after fully understanding the study's purpose, methods, and potential risks. - Boys who are able to walk and are aged 4 years old up to (but not including) 9 years old. - A confirmed mu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07086521 · Restem, LLC. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 September 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 15 years or older. - People who have a confirmed genetic diagnosis of FSHD type 1 or FSHD type 2. - People whose FSHD symptoms score at least 3 out of 10 on a standard clinical severity scale, and who are able to walk independently at the time of the study. - Peo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07092540 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2029
🇺🇸 US

**Who might be able to join this trial:** - The child must be a boy between birth and 3 years old at the time of joining the trial - The child must have a confirmed genetic test result showing a known or likely harmful change in the DMD gene - A parent or guardian must be able to understand the study and sign a written...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07118280 · Sheba Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇮🇱 IL

Who might be able to join this trial: - You have been diagnosed with OPMD (a hereditary muscle disease called oculopharyngeal muscular dystrophy) - You are the spouse or someone who lives in the same household as a person diagnosed with OPMD Who may not be able to join: - You are currently pregnant - You have any cond...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07125040 · Università Vita-Salute San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with LAMA2-related muscular dystrophy, confirmed by either: two specific gene changes (mutations) in the LAMA2 gene, OR a muscle biopsy showing absence of a protein called merosin along with at least one LAMA2 gene mutation, OR a matching set of sympto...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07129954 · Universita di Verona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with one of these types of muscular dystrophy: myotonic, facio-scapulo-humeral, Becker, limb-girdle, Emery-Dreifuss, or distal muscular dystrophy - People between 16 and 65 years of age - People who still have some ability to walk, even if only...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07138963 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with a congenital myopathy (a muscle condition present from birth) or a congenital muscular dystrophy (an inherited muscle-weakening condition present from birth) - You are under 18 years of age - Both boys and girls can take part - Your muscle condition h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07146256 · Sheba Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇮🇱 IL

Who might be able to join this trial: - You have been diagnosed with a condition called OPMD (Oculopharyngeal Muscular Dystrophy), or you have signs or symptoms that may suggest you could have OPMD (confirm with trial site) Who may not be able to join: - You are under 18 years of age - You are currently pregnant Impo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07172971 · Vanderbilt University Medical Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Duchenne Muscular Dystrophy (DMD), confirmed by a muscle biopsy or genetic test - A special heart scan (called a cardiac MRI) has shown specific changes in your heart tissue (known as late gadolinium enhancement) - Your heart's pumping ability is eith...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07188012 · Shanghai Siponuoyin Biotechnology Co Ltd Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - The patient (and/or their legal guardian) has read, understood, and signed a consent form agreeing to take part in the study. - The patient is a boy aged 2 years or older but under 8 years old, and can walk at least 10 meters on his own. - The patient has been diagnosed with...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07220603 · PepGen Inc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2029
🇨🇦 CA

Who might be able to join this trial: - You must have already completed a previous study involving the drug PGN-EDODM1 Who may not be able to join: - Your blood or lab test results at the start of the screening process show abnormal results that the doctor considers medically significant - You have taken part in anoth...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07332013 · Children's Hospital of Philadelphia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇺🇸 US

Who might be able to join this trial: **If your child has DMD or BMD (Duchenne or Becker Muscular Dystrophy):** - Your child is able to walk on their own at the time of screening - Your child has been diagnosed with DMD or BMD confirmed through genetic testing - A parent or guardian is able to give permission for thei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07362875 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2029
🇺🇸 US

Who might be able to join this trial: **For people with myotonic dystrophy (DM):** - You are between 18 and 65 years old - You have been diagnosed with myotonic dystrophy type 1 or type 2, either through genetic testing or by a doctor based on your symptoms (if diagnosed by symptoms only, a close blood relative must h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07378553 · Nantes University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 March 2029
🇫🇷 FR

Who might be able to join this trial: - Males aged 5–30 who have been diagnosed with Duchenne Muscular Dystrophy (a muscle-weakening condition), whether or not they are still able to walk - Males aged 5–60 who have been diagnosed with Becker Muscular Dystrophy (a related muscle condition), confirmed by genetic testing...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07385443 · Fundació Institut Germans Trias i Pujol Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇪🇸 ES

Who might be able to join this trial: - You have been diagnosed with Myotonic Dystrophy Type 1 (a muscle condition) and this has been confirmed through a genetic test. Who may not be able to join: - There are no specific reasons listed that would stop someone from joining this registry. Important: Always verify eligi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07409142 · FSHD Society Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2060
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with FSHD (a muscle condition) either through a doctor's assessment or a genetic test, or you have family members with FSHD and are experiencing symptoms yourself - You are 1 year of age or older - You currently live in the United States or one of its terr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07415837 · University Hospital, Clermont-Ferrand Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇫🇷 FR

Who might be able to join this trial: - You must be older than 2 years of age - You (or your parent/legal guardian) must agree to take part — children under 6 give spoken agreement, and those over 6 give written agreement - You must be registered with the French social security system - You must have been diagnosed wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07423026 · University of Oxford Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇬🇧 GB

**Who might be able to join this trial:** *For a child with DMD:* - The child must be male - The child must be between 1 and 3 years old - The child must be able to walk at least 10 metres on their own - The child must have a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) through genetic testing - The parent...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07429240 · Precision BioSciences, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2029
🇺🇸 US

**Who might be able to join this trial:** - Boys between 2 and 7 years old (inclusive) at the time of consent - Boys who have a confirmed DMD diagnosis through genetic testing, where the specific gene change falls within a region known as exons 45 to 55 - Boys whose symptoms match what doctors typically see in DMD, as...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07436143 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 February 2026
🇵🇰 PK

Who might be able to join this trial: - Children who have been diagnosed with Duchenne muscular dystrophy and are between 5 and 9 years old Who may not be able to join: - Children who have a metabolic disorder (a condition affecting how the body processes energy or nutrients) - Children who have a disorder caused by a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07486934 · Dyne Therapeutics Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 1 July 2028
🇧🇪 BE🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇪🇸 ES🇬🇧 GB +1 more

Who might be able to join this trial: - People who have been diagnosed with a condition called myotonic dystrophy type 1 (DM1), confirmed by a genetic test showing a specific genetic repeat number greater than 100 (past test results from clinical testing are acceptable). - People who are able to walk 10 metres and stan...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07502989 · Beth Israel Deaconess Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 89 years old - You have been diagnosed with a primary muscle disease, confirmed through genetic testing, blood tests, or a previous muscle biopsy **Who may not be able to join:** - You are unable to lie flat or have a history of claustrophobia (fear of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07505342 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 88 years of age - People who have been clinically diagnosed with Myotonic Dystrophy Type 1 (DM1), a muscle condition - People who speak English - People who are able to give informed consent (meaning they can understand and agree to take part in the study) -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07515235 · Aristotle University Of Thessaloniki Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇬🇷 GR

**Who might be able to join this trial:** - You are male - You are between 2 and 24 years old at the time of joining the trial - You have been diagnosed with a dystrophinopathy (a muscle disease related to the DMD gene) that has been confirmed through genetic testing - Your genetic diagnosis was made using at least one...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07543016 · University of Pavia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with Facioscapulohumeral Muscular Dystrophy (FSHD), confirmed by a genetic test - You are between 18 and 50 years old - Your FSHD has been classified into a specific group that includes the most typical signs of the disease, such as weakness in the fa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07608432 · Dyne Therapeutics Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2030
🇺🇸 US

**Who might be able to join this trial:** - You are a male who can walk and has been diagnosed with Duchenne muscular dystrophy (DMD), with a specific type of genetic change that could be helped by a treatment called "exon 51 skipping" - You are able to get up from the floor in under 10 seconds, and this was confirmed...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07609394 · The Duchenne Registry Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2035
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Duchenne muscular dystrophy, Becker muscular dystrophy, or you are a female carrier of one of these conditions - You are a patient at a healthcare facility that is already connected to PPMD's Interchange system through their electronic health records...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07630389 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇺🇸 US

Who might be able to join this trial: - The child or young person must be between 0 and 17 years old - They must have been diagnosed with congenital, childhood, or juvenile myotonic dystrophy type 1 (DM1, a specific inherited muscle condition) - The child and/or their parent or guardian must be able to speak English -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07673809 · AO GENERIUM Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 2 August 2029
Belarus🇷🇺 RU

**Who might be able to join this trial:** - The patient (or their parent/guardian) must give written agreement to take part in the trial - The patient must be a boy aged 4 to 9 years old who can walk and has been officially diagnosed with Duchenne muscular dystrophy (DMD) with symptoms of the disease - The patient mus...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07674758 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2029
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with Duchenne muscular dystrophy, Becker muscular dystrophy, or are a muscular dystrophy carrier, confirmed through a muscle biopsy or genetic test Who may not be able to join: - You have another genetic or birth-related condition that could affect how yo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07700225 · Virginia Commonwealth University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2032
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 70 years old (inclusive). - People who are able to provide written, voluntary consent before any study procedures begin — or, where a legal representative provides consent on someone's behalf, verbal agreement from the person themselves, with consent capacity as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07711730 · University of Deusto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇪🇸 ES

Who might be able to join this trial: - People who have been diagnosed with limb-girdle muscular dystrophy (a condition that affects the muscles around the hips and shoulders) - People who are between 7 and 17 years old - People whose legal guardians have signed a consent form before the study begins - People for whom...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Muscular Dystrophy. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

Two national bodies are active: Muscular Dystrophy Australia, which has supported people since 1984, and Muscular Dystrophy Foundation Australia, which coordinates a national voice across state and territory member groups.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.